Oncogenic osteomalacia in a case with a maxillary sinus mesenchymal tumor

American Journal of the Medical Sciences

Volumn 332, Issue 3, 2006, Pages 142-147

  Koriyama, Nobuyuki ^a,b   Nishimoto, Kengo ^a   Kodama, Takuro ^a   Nakazaki, Mitsuhiro ^a   Kurono, Yuichi ^a   Yoshida, Hiroki ^a   Tei, Chuwa ^a  

^a KAGOSHIMA UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KAGOSHIMA MEDICAL CENTER   (Japan)

Author keywords

FGF23; Hypophosphatemia; Mesenchymal tumor; Oncogenic osteomalacia

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; MEDRONATE TECHNETIUM TC 99M; PHOSPHATE;

ADULT; ANAMNESIS; ARTICLE; BONE REMODELING; BONE SCINTISCANNING; CANCER SURGERY; CASE REPORT; CHEMICAL ANALYSIS; CHRONIC PAIN; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE TUMOR; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; MAXILLA SINUS TUMOR; MESENCHYMOMA; ONCOGENIC OSTEOMALACIA; OSTEOMALACIA; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 33748742433     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200609000-00010     Document Type: Article

References (27)

1. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia- associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004;28:1-30.
2. Drezner MK. Tumor-induced osteomalacia. Rev Endocr Metab Disord 2001;2:175-86.
3. Gonzalez-Compta X, Mañós-Pujol M, Foglia-Fernandez M, et al. Oncogenic osteomalacia: case report and review of head and neck associated tumours. J Laryngol Otol 1998;112:389-92.
4. Weidner N, Cruz DS. Phosphaturic mesenchymal tumors: a polymorphous group causing osteomalacia or rickets. Cancer 1987;59:1442-54.
5. Econs MJ, Drezner MK. Tumor-induced osteomalacia: unveiling a new hormone. N Engl J Med 1994;330:1679-81.
6. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001;98:6500-6505.
7. White KE, Evans WE, O'Riordan JL, et al. Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345-8.
8. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002;87:4957-60.
9. Fukagawa M, Nii-Kono T, Kazama JJ. Role of fibroblast growth factor 23 in health and chronic kidney disease. Curr Opin Nephrol Hypertens 2005;14:325-9.
10. Liu S, Guo R, Simpson LG, et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003;278:37419-26.
11. Larsson T, Zahradnik R, Lavigne J, et al. Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia. Eur J Endocrinol 2003;148:269-76.
12. Nelson AE, Bligh RC, Mirams M, et al. Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab 2003;88:4088-94.
13. Murer H, Hernando N, Foster I, et al. Regulation of Na/Pi transporter in the proximal tubule. Annu Rev Physiol 2003;65:531-42.
14. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-35.
15. 3 production. J Biol Chem 2003;278:2206-11.
16. Takeuchi Y, Suzuki H, Ogura S, et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 2004;89:3979-82.
17. McCance RA. Osteomalacia with Loosers nodes (Milkmans syndrome) due to the raised resistance to vitamin D acquired about the age of 15 years. Q J Med 1947;16:33-47.
18. Prader A, Illig R, Uehlinger RE, et al. Rickets caused by bone tumors. Helv Pediatr Acta 1959;14:554-65.
19. Econs ML, McEnery PT. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 1997;82:674-81.
20. Seufert J, Ebert K, Müller J, et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 2001;345:1883-8.
21. Rhee Y, Lee JD, Shin KH, et al. Oncogenic osteomalacia associated with mesenchymal tumor detected by indium-111 octreotide scintigraphy. Clin Endocrinol (Oxf) 2001;54:551-4.
22. Nguyen BD, Wang EA. Indium-111 pentreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med 1999;24:130-31.
23. Jan de Beur SM, Streeten EA, Civelek AC, et al. Localization of mesenchymal tumours by somatostatin receptor imaging. Lancet 2002;359:761-3.
24. Dupond JL, Mahammedi H, Prié D, et al. Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT SCAN for the diagnosis and follow-up in one case. Bone 2005;36:375-8.
25. Ryan WG, Gitelis S, Charters JR. Studies in a patient with tumor-induced hypophosphatemic osteomalacia. Calcif Tissue Int 1986;38:358-62.
26. Yang IM, Park YK, Hyun YJ, et al. Oncogenic osteomalacia caused by a phosphaturic mesenchymal tumor of the oral cavity: a case report. Korean J Intern Med 1997;12:89-95.
27. Shigematsu T, Kazama JJ, Yamashita T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004;44:250-6.